Burden of Venous Thromboembolism in Patients with Pancreatic Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2021 May 27

PMID 34040325

Citations 9

Authors

Corinne Frere

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer (PC) is a devastating malignancy with fewer than 10% of patients being alive at 5 years after diagnosis. Venous thromboembolism (VTE) occurs in approximatively 20% of patients with PC, resulting in increased morbidity, mortality and significant health care costs. The management of VTE is particularly challenging in these frail patients. Adequate selection of the most appropriate anticoagulant for each individual patient according to the current international guidelines is warranted for overcoming treatment challenges. The International Initiative on Thrombosis and Cancer multi-language web-based mobile application (downloadable for free at www.itaccme.com) has been developed to help clinicians in decision making in the most complex situations. In this narrative review, we will discuss the contemporary epidemiology and burden of VTE in PC patients, the performances and limitations of current risk assessment models to predict the risk of VTE, as well as evidence from recent clinical trials for the primary prophylaxis and treatment of cancer-associated VTE that support up-dated clinical practice guidelines.

Citing Articles

Clot formation, structure, and fibrinolysis of pancreatic cancer patients.

Risman R, Milman N, Sinan H, Tutwiler V Res Sq. 2025; .

PMID: 39989974 PMC: 11844638. DOI: 10.21203/rs.3.rs-5868575/v1.

Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies.

Vladic N, Englisch C, Ay C, Pabinger I Res Pract Thromb Haemost. 2025; 9(1):102664.

PMID: 39877524 PMC: 11772966. DOI: 10.1016/j.rpth.2024.102664.

Pulmonary Embolism in Long Standing Diabetes: A Hint Towards Pancreatic Carcinoma.

Shrestha A, Haas C J Community Hosp Intern Med Perspect. 2025; 15(1):118-122.

PMID: 39867139 PMC: 11759090. DOI: 10.55729/2000-9666.1429.

Study of Coagulation Parameters in Gastrointestinal Malignancies.

Patil G, Kanetkar S Cureus. 2024; 16(10):e72162.

PMID: 39583495 PMC: 11582017. DOI: 10.7759/cureus.72162.

Efficacy of ferric carboxymaltose or darbepoetin alfa for chemotherapy-induced anemia in patients with esophagogastric or pancreaticobiliary cancer: a retrospective comparative study.

Cho M, Park E, Lee Y, Kim H, Park H, Kim H Ther Adv Med Oncol. 2024; 16:17588359241265209.

PMID: 39091605 PMC: 11292682. DOI: 10.1177/17588359241265209.

References

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

den Exter P, Hooijer J, Dekkers O, Huisman M . Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011; 29(17):2405-9. DOI: 10.1200/JCO.2010.34.0984. View

Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana A . International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016; 17(10):e452-e466. DOI: 10.1016/S1470-2045(16)30369-2. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Key N, Khorana A, Kuderer N, Bohlke K, Lee A, Arcelus J . Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019; 38(5):496-520. DOI: 10.1200/JCO.19.01461. View

van Es N, Franke V, Middeldorp S, Wilmink J, Buller H . The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2016; 150:30-32. DOI: 10.1016/j.thromres.2016.12.013. View

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

Boone B, Zenati M, Rieser C, Hamad A, Al-Abbas A, Zureikat A . Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. Ann Surg Oncol. 2019; 26(5):1503-1511. DOI: 10.1245/s10434-018-07148-z. View

Kraaijpoel N, Bleker S, Meyer G, Mahe I, Munoz A, Bertoletti L . Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. J Clin Oncol. 2019; 37(20):1713-1720. DOI: 10.1200/JCO.18.01977. View

10.

Mier-Hicks A, Raj M, Do R, Yu K, Lowery M, Varghese A . Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. Clin Colorectal Cancer. 2018; 17(2):121-128. PMC: 7382360. DOI: 10.1016/j.clcc.2018.01.008. View

11.

Spencer F, Lessard D, Emery C, Reed G, Goldberg R . Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007; 167(14):1471-5. PMC: 2762787. DOI: 10.1001/archinte.167.14.1471. View

12.

Martin A, Garcia Alfonso P, Ruperez Blanco A, Perez Ramirez S, Blanco Codesido M, Martin Jimenez M . Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model. Clin Transl Oncol. 2014; 16(10):927-30. DOI: 10.1007/s12094-014-1165-y. View

13.

Mitry E, Taleb-Fayad R, Deschamps A, Mansencal N, Lepere C, Declety G . Risk of venous thrombosis in patients with pancreatic adenocarcinoma. Gastroenterol Clin Biol. 2008; 31(12):1139-42. DOI: 10.1016/s0399-8320(07)78352-5. View

14.

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L . Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10(10):943-9. DOI: 10.1016/S1470-2045(09)70232-3. View

15.

Khorana A, Kuderer N, Culakova E, Lyman G, Francis C . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902-7. PMC: 2384124. DOI: 10.1182/blood-2007-10-116327. View

16.

Mandala M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S . Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol. 2007; 18(10):1660-5. DOI: 10.1093/annonc/mdm284. View

17.

Afsar C, Gunaldi M, Kum P, Sahin B, Erkisi M, Kara I . Pancreatic carcinoma, thrombosis and mean platelet volume: single center experience from the southeast region of Turkey. Asian Pac J Cancer Prev. 2014; 15(21):9143-6. DOI: 10.7314/apjcp.2014.15.21.9143. View

18.

Heit J . Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; 12(8):464-74. PMC: 4624298. DOI: 10.1038/nrcardio.2015.83. View

19.

Faille D, Bourrienne M, de Raucourt E, de Chaisemartin L, Granger V, Lacroix R . Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget. 2018; 9(41):26453-26465. PMC: 5995170. DOI: 10.18632/oncotarget.25458. View

20.

Oh S, Kim J, Lee K, Bang S, Hwang J, Oh D . Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res. 2008; 122(4):485-90. DOI: 10.1016/j.thromres.2007.12.015. View